-
Trishakti Industries Limited Q3 FY23 Net Sales at Rs 99.38 crore, up 34.7% YoY
Trishakti Industries Limited reported a 34.7% increase in net sales to Rs 99.38 crore for the third quarter ended December 2022, compared to Rs 73.79 crore in the same period last year.
-
Trishakti Industries Limited Declares Interim Dividend of Rs 2.50 per share
Trishakti Industries Limited has declared an interim dividend of Rs 2.50 per equity share for the financial year 2022-23.
-
Trishakti Industries Limited Launches New Product Line
Trishakti Industries Limited has launched a new product line of LED lighting solutions.
-
Trishakti Industries Q4 Net Profit Jumps 133%
Trishakti Industries reported a 133% increase in its net profit for the fourth quarter ended March 31, 2023. The company reported a net profit of Rs. 23.24 crore, compared to Rs. 10.01 crore in the same period last year.
-
Trishakti Industries to Invest Rs. 100 Crore in New Plant
Trishakti Industries plans to invest Rs. 100 crore to set up a new plant in Gujarat. The new plant will boost the company's production capacity by 50%.
-
Trishakti Industries Signs MOU with Global Partner
Trishakti Industries has signed a memorandum of understanding (MOU) with a global partner to distribute its products in overseas markets.
-
Trishakti Industries Limited Reports Strong Quarterly Results
Trishakti Industries Limited (TIL), a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates, has reported strong financial results for the quarter ended June 30, 2023.
-
Trishakti Industries Limited Receives US FDA Approval for New API Facility
Trishakti Industries Limited (TIL) has received approval from the United States Food and Drug Administration (US FDA) for its new API manufacturing facility in Hyderabad, India.
-
Trishakti Industries Limited Partners with Leading Global Pharma Company
Trishakti Industries Limited (TIL) has announced a strategic partnership with a leading global pharmaceutical company to develop and manufacture a novel API for the treatment of cancer.